Disclaimer
is Pocket Guide attempts to define principles of practice that should produce high-quality
patient care. It is applicable to specialists, primary care, and providers at all levels. is
Pocket Guide should not be considered exclusive of other methods of care reasonably directed
at obtaining the same results. e ultimate judgment concerning the propriety of any course of
conduct must be made by the clinician aer consideration of each individual patient situation.
International Guidelines Center (IGC), the medical associations, nor the authors endorse any
product or service associated with the distributor of this clinical reference tool.
Abbreviations
ADM, adalimumab; AS, ankylosing spondylitis; BSA, body surface area; CD20i, CD20
inhibitor; cDMARDs, conventional disease modifying anti-rheumatic drugs; CS,
corticosteroids; CyA, cyclosporine; CZP, certolizumab; DIP, distal interphalangeal joint;
DMARDs, disease modifying anti-rheumatic drugs; ETN, etanercept; GOL, golimumab;
IA, intra articular; IL6i, interleukin 6 inhibitor; IL17i, interleukin 17 inhibitor;
IL12/23i, interleukin 12/23 inhibitor; INF, infliximab; LEF, leflunomide; MTX,
methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PDE4i, phosphodiesterase
4 inhibitor [apremilast]; PIP, proximal interphalangeal joint; SEC, secukinumab; SIJ,
sacroiliac injections; SJ, swollen joint; SSZ, sulfasalazine; TNFi, tumor necrosis factor
inhibitor; TJ, tender joint
Source
Coates LC, Kavanaugh A, Mease PJ et al. Group for Research and Assessment of Psoriasis
and Psoriatic Arthritis: Treatment Recommendations for Psoriatic Arthritis 2015.
GRAPSO16033e
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2016 All rights reserved
